Adverum Biotechnologies, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Peter Soparkar. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Peter Soparkar has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ADVM / Adverum Biotechnologies, Inc. CHIEF OPERATING OFFICER 39,154
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Peter Soparkar. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ADVM / Adverum Biotechnologies, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADVM / Adverum Biotechnologies, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-04-19 ADVM Soparkar Peter 175 1.1373 18 11.3730 199 85 1.7500 -169 -85.05
2022-04-19 ADVM Soparkar Peter 21,750 1.1400 2,175 11.4000 24,795
2021-12-08 ADVM Soparkar Peter 25,000 1.9100 2,500 19.1000 47,750
2020-08-17 ADVM Soparkar Peter 7,692 13.0000 769 130.0000 99,996

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADVM / Adverum Biotechnologies, Inc. Insider Trades
Insider Sales ADVM / Adverum Biotechnologies, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADVM / Adverum Biotechnologies, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-05-15 ADVM Soparkar Peter 2,960 2.0000 2,960 2.0000 5,920 0 2.0500 148 2.50
2023-03-15 ADVM Soparkar Peter 13,360 0.7816 1,336 7.8160 10,442
2022-09-19 ADVM Soparkar Peter 13,305 1.0697 1,330 10.6970 14,232

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADVM / Adverum Biotechnologies, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Peter Soparkar as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-05-16 2025-05-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale -2,960 39,154 -7.03 2.00 -5,920 78,308
2025-02-27 2025-02-25 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
A - Award 13,125 42,114 45.28
2023-03-17 2023-03-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale -13,360 265,891 -4.78 0.78 -10,442 207,820
2022-09-21 2022-09-19 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale -13,305 273,251 -4.64 1.07 -14,232 292,297
2022-04-20 2022-04-19 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 21,750 280,556 8.40 1.14 24,795 319,834
2022-04-20 2022-04-19 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 175 258,806 0.07 1.14 199 294,340
2022-03-17 2022-03-08 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 255,000 255,000
2021-12-10 2021-12-08 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 25,000 258,631 10.70 1.91 47,750 493,985
2021-08-10 2021-08-06 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 160,000 160,000
2021-08-10 2021-08-06 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
A - Award 220,000 230,692 2,057.61
2021-02-18 2021-02-16 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 140,000 140,000
2020-08-19 2020-08-17 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
P - Purchase 7,692 10,692 256.40 13.00 99,996 138,996
2020-02-21 2020-02-20 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 40,750 40,750
2019-11-01 2019-10-30 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 400,000 400,000
2019-11-01 3 ADVM Adverum Biotechnologies, Inc.
No securities owned.
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)